Alpha Cognition (NASDAQ:ACOG) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright began coverage on shares of Alpha Cognition (NASDAQ:ACOG) in a research note published on Tuesday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $20.00 price target on the stock. HC Wainwright also issued estimates for Alpha Cognition’s Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($2.02) EPS, Q1 2026 earnings at ($0.51) EPS, Q2 2026 earnings at ($0.45) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.29) EPS and FY2026 earnings at ($1.67) EPS.

Alpha Cognition Stock Down 2.6 %

ACOG stock opened at $5.55 on Tuesday. The stock has a market cap of $88.91 million, a price-to-earnings ratio of -2.17 and a beta of 2.50. Alpha Cognition has a twelve month low of $4.66 and a twelve month high of $7.00. The firm’s 50-day moving average is $5.92.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Sphera Funds Management LTD. purchased a new position in Alpha Cognition during the 4th quarter valued at about $3,652,000. Bleichroeder LP purchased a new position in Alpha Cognition during the 4th quarter valued at about $1,024,000. Alyeska Investment Group L.P. purchased a new position in Alpha Cognition during the 4th quarter valued at about $2,356,000. Manatuck Hill Partners LLC purchased a new position in Alpha Cognition during the 4th quarter valued at about $395,000. Finally, Tudor Investment Corp ET AL bought a new stake in shares of Alpha Cognition during the 4th quarter valued at about $412,000.

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.